Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Glomerulonephritis, IGA

• A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
• A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
• A Study of BION-1301 in Adults With IgA Nephropathy
• Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
• A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
• A Study of Telitacicept in Patients With Primary IgA Nephropathy
• A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
• An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases.
• A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
• Phase III Study of Telitacicept in Patients With IgA Nephropathy
• Efficacy and Safety in Chinese Patients With IgA Nephropathy Who Have Completed Study Nef-301
• Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject
• Bortezomib for Treating Glomerular Diseases
• Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
• Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
• BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)
• Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
• Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
• Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal Disease
• Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
• A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
• A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
• A Trial of HR19042 Capsule in Healthy Chinese Subjects
• Steroids Therapy in IgA Nephropathy With Crescents
• Open-Label Extension Study of BION-1301 in IgA Nephropathy
• A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
• Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
• Atrasentan in Patients With Proteinuric Glomerular Diseases
• Atrasentan in Patients With IgA Nephropathy
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
• Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
• Rituximab and RASi in Patients With IgAN
• Safety and Efficacy Study of VIS649 for IgA Nephropathy
• Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
• Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
• A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
• Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
• A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
• A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
• Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
• Effect of Immunosuppression in IgA Nephropathy
• Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
• Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD
• Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
• Treatment of IgA Nephropathy According to Renal Lesions
• Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
• Efficacy and Safety of Atacicept in IgA Nephropathy
• Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
• Integrative Medicine of IgA Nephropathy
• Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
• Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
• Rituximab in Recurrent IgA Nephropathy
• Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
• Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
• Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade
• Acthar on Proteinuria in IgA Nephropathy Patients
• Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study
• Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
• Efficacy and Safety of Losartan in Children With Ig A Nephropathy
• Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
• Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.
• A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.
• Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
• BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
• BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
• Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath
• The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
• Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
• The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
• Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
• The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy
• Steroids and Azathioprine in Advanced IgAN
• An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)
• Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers
• Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
• A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
• A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy
• Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
• Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
• Pilot Study of Velcade® in IgA Nephropathy
• Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
• Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
• Aliskiren for Immunoglobulin A (IgA) Nephropathy
• Mycophenolate Mofetil for IgA Nephropathy
• Calcitriol in the Treatment of Immunoglobulin A Nephropathy
• A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
• Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
• "Steroids and Azathioprine Versus Steroids Alone in IgAN"
• Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
• Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
• Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
• Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy
• Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
• Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
• Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
• A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
• Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy
• ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
• Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
• Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy
• Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
• Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy
• Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy
• Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy